Two DNMT inhibitors (DNMTi), decitabine and azacitidine, were shown to be effective in inhibiting the tumorigenic effects of translocated MYC in BL, in some forms of DLBCL, and in other types of non-Hodgkin lymphoma [147,148]. This evidence concerns the gene MYC and Burkitt lymphoma.